Effect of zoledronic acid on bone metabolism in prostate cancer (T3NXMO) patients on the androgen deprivation

被引：0
|
作者：
不详
机构：
来源：
EUROPEAN UROLOGY SUPPLEMENTS | 2006年 / 5卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：205 / 205
页数：1
相关论文
共 50 条
  • [1] The effects of intermittent androgen deprivation therapy (ADT) and zoledronic acid administration on bone density in patients with prostate cancer
    Katznelson, L.
    Kent, K.
    Srinivas, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [2] Zoledronic acid as adjunct to androgen deprivation therapy reduces bone loss in men with prostate cancer
    不详
    EUROPEAN UROLOGY SUPPLEMENTS, 2006, 5 (02) : 57 - 57
  • [3] Effect of zoledronic acid on bone loss associated with androgen blockade for prostate cancer
    Casey, R
    Love, W
    Pearson, D
    Reymond, D
    Zarenda, M
    BONE, 2004, 34 : S84 - S84
  • [4] Androgen deprivation causes bone loss and increased prostate cancer metastases to bone: Prevention by zoledronic acid.
    Padalecki, SS
    Carreon, MR
    Grubbs, B
    Cui, Y
    Guise, TA
    JOURNAL OF BONE AND MINERAL RESEARCH, 2002, 17 : S310 - S310
  • [5] Frequency of zoledronic acid to prevent further bone loss in osteoporotic patients undergoing androgen deprivation therapy for prostate cancer
    Wadhwa, Vivek K.
    Weston, Robin
    Parr, Nigel J.
    BJU INTERNATIONAL, 2010, 105 (08) : 1082 - 1088
  • [6] Frequency of zoledronic acid to prevent bone loss in osteoporotic patients requiring androgen-deprivation therapy for prostate cancer
    Wadhwa, V. K.
    Weston, R.
    Parr, N. J.
    BJU INTERNATIONAL, 2007, 99 : 37 - 37
  • [7] The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy
    Israeli, Ron S.
    Rosenberg, Steven J.
    Saltzstein, Daniel R.
    Gottesman, James E.
    Goldstein, Howard R.
    Hull, Gerald W.
    Tran, Diep N. H.
    Warsi, Ghulam M.
    Lacerna, Leo V.
    CLINICAL GENITOURINARY CANCER, 2007, 5 (04) : 271 - 277
  • [8] Zoledronic acid to prevent bone loss in Chinese men receiving androgen deprivation therapy for prostate cancer
    Yee, Chi-hang
    Ng, Chi-fai
    Wong, Annie Y. F.
    Chan, Chi-kowk
    Hou, See-ming
    Yip, Sidney K. H.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2011, 7 (02) : 168 - 173
  • [9] Bone health: the effect of androgen deprivation therapy in prostate cancer patients
    Drudge-Coates, Lawrence
    INTERNATIONAL JOURNAL OF UROLOGICAL NURSING, 2007, 1 (01) : 18 - 26
  • [10] Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer
    Ryan, Christopher W.
    Huo, Dezheng
    Demers, Laurence M.
    Beer, Tomasz M.
    Lacerna, Leo V.
    JOURNAL OF UROLOGY, 2006, 176 (03): : 972 - 978
12345